Biomarkers of exposition_Uchuva Dorada |
17/04/2018 |
kmunoz |
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors |
17/02/2017 |
CIM |
Oropharyngeal sanitization with electrolyzed superoxidation solution with neutral pH to prevent COVID-19 |
16/03/2021 |
SSA |
Phase I with CIGB-814 in rheumatoid arthritis patients |
16/02/2017 |
CIGB |
Ozone-Therapy-Immunoglobulin A deficiency-adults and childrens-Phase II |
16/02/2017 |
HGM |
EC122 HER-1 Prostate Phase I |
15/11/2016 |
CIM |
Bioactive formulation to treat osteoarthritis |
15/08/2017 |
SSA |
Phenamate in the treatment of prostate cancer |
15/08/2017 |
SSA |
CIMAvax-EGF vaccine Predictor Phase IV |
14/12/2015 |
CIM |
Study in Hematological Malignancies |
14/11/2014 |
CIGB |
Study of intensive pediatric pharmacovigilance of nimotuzumab for the treatment of malignant glioma tumors. |
14/08/2014 |
CIMAB |
CIGB-258 at COVID-19 |
14/05/2020 |
CIGB |
Coffee-bioavailability-cardiovascular health |
13/09/2013 |
kmunoz |
Policosanol for long term-Ictus |
13/09/2013 |
CPN |
SOBERANA PLUS TURIN |
12/11/2021 |
FINLAY |
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer |
12/03/2019 |
ROCHE |
Randomized double blind controlled, phase I clinical trial, to assess safety, reactogenicity and immunogenicity of the 638 vaccine candidate, in healthy female and male children and adolescents aged from 5 to 17 years old from Cienfuegos Province, Cuba. |
11/10/2013 |
FINLAY |
CIMAvax-EGF in Bladder cancer |
11/08/2020 |
CIM |
Biograft-G in Dentistry |
11/03/2016 |
BIOMAT |
Dermofural-diabetic foot ulcers |
11/03/2016 |
CBQ |